Linked Life Data

11846327

Source:http://linkedlifedata.com/resource/pubmed/id/11846327

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2002-2-15
pubmed:abstractText
We treated 116 healthy postmenopausal women (age 47-66 years, mean 57 years) in Taiwan with either raloxifene (RLX) 60 mg (n = 92) or 0.625 mg conjugated equine estrogen plus 5 mg medroxyprogesterone acetate (CCEP, n = 24) daily for 12 months in a randomized, double-masked, active-controlled fashion. The results showed that both regimens increased bone mineral density (BMD) at hip sites (means: RLX 2.5-4.9%, CCEP 4.6-7.9%, all p<0.005 compared with baseline), and the difference between the two regimens was not significant. The spinal BMD increased significantly in both groups (1.4% with RLX and 6.0% with CCEP, both p<0.01), and more with CCEP (p<0.003). Osteocalcin levels and urinary type I collagen C-telopeptide/creatinine ratios decreased significantly in both regimens, but the decreases were significantly larger with CCEP. Compared with baseline, both RLX and CCEP decreased the total cholesterol (median 4.9% and 8.6% respectively, p<0.001) and LDL-cholesterol (median 11% and 19% respectively, p<0.001), and increased HDL-cholesterol (median 8.6% and 10.7% respectively, p<0.01). Both regimens increased triglyceride levels (median 3.2% and 18.9% respectively, both p<0.05), although to a lesser extent with RLX than with CCEP (p<0.05). Only 3 subjects (3.3%) reported vaginal bleeding in the RLX group, as compared with 31% (7/22) with CCEP (p<0.05). We conclude that in healthy, postmenopausal Taiwanese women, RLX 60 mg given daily has favorable results in BMD, bone turnover and serum lipids, although the dosage we used showed a potency less than that of conventional CCEP.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0937-941X
pubmed:author
pubmed:issnType
Print
pubmed:volume
12
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1020-5
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:11846327-Aged, pubmed-meshheading:11846327-Bone Density, pubmed-meshheading:11846327-Double-Blind Method, pubmed-meshheading:11846327-Drug Combinations, pubmed-meshheading:11846327-Endometrium, pubmed-meshheading:11846327-Estrogen Replacement Therapy, pubmed-meshheading:11846327-Estrogens, Conjugated (USP), pubmed-meshheading:11846327-Female, pubmed-meshheading:11846327-Hip Joint, pubmed-meshheading:11846327-Humans, pubmed-meshheading:11846327-Lipids, pubmed-meshheading:11846327-Lumbar Vertebrae, pubmed-meshheading:11846327-Medroxyprogesterone Acetate, pubmed-meshheading:11846327-Middle Aged, pubmed-meshheading:11846327-Postmenopause, pubmed-meshheading:11846327-Progesterone Congeners, pubmed-meshheading:11846327-Raloxifene, pubmed-meshheading:11846327-Selective Estrogen Receptor Modulators, pubmed-meshheading:11846327-Uterus
pubmed:year
2001
pubmed:articleTitle
Raloxifene versus continuous combined estrogen/progestin therapy: densitometric and biochemical effects in healthy postmenopausal Taiwanese women.
pubmed:affiliation
Department of Laboratory Medicine, National Taiwan University Hospital and Medical College, Taipei, ROC.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study